This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preservedejectionfraction (HFpEF). of patients had BMI ≥30 kg/m 2. Strain measurements in all four chambers were maintained as BMI increased. Overall, 60.9%
BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejectionfraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. In addition, dapagliflozin was safe and well-tolerated, irrespective of COPD status.
Background: Patients with heart failure, a preservedejectionfraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. n=393) were female; BMI 38.26.7kg/m2, KCCQ-CSS 53.518.5, n=393) were female; BMI 38.26.7kg/m2, KCCQ-CSS 53.518.5, Circulation, Ahead of Print.
Background:Patients with heart failure (HF) with preservedejectionfraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 mg or placebo for 52 weeks.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
BMI 
40 
Let's personalize your content